Anika reports first quarter 2024 financial results

Revenue up 7% on growing demand and favorable order timing; on-track for 2024 revenue guidance cost reduction initiatives complete; on-track to achieve 2024 adjusted ebitda guidance of $25-30 million, up over 75% at the midpoint bedford, mass., may 08, 2024 (globe newswire) -- anika therapeutics, inc. (nasdaq: anik), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended march 31, 2024.
ANIK Ratings Summary
ANIK Quant Ranking